Erschienen in:
04.08.2016 | Thoracic Oncology
Gastroesophageal Junction Tumors
verfasst von:
Nabil Rizk, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 12/2016
Einloggen, um Zugang zu erhalten
Excerpt
The persistent debate regarding the management of gastroesophageal (GE) junction tumors is somewhat of a self-inflicted wound, in that its roots can be attributed to a single group that popularized both the nomenclature and the treatment strategy,
1 , 2 but for which no large retrospective study has since adequately investigated, for which the biologic and anatomic bases for the distinction are thin,
3 – 5 and for which prospective randomized trials that included theses GE junction tumors treated them variably as gastric cancers
6 , 7 or esophageal cancers.
8 Consequently, despite firm convictions on how to manage these tumors, we in fact currently have very little useful information from which to base the clinical treatment of these tumors. The level of evidence used to support various recommendations would be considered primarily level III using the US Preventive Task Force criteria, and the practice recommendations would be grade C as a consequence. …